bootstrap_f2 {disprofas} | R Documentation |
Bootstrap f2
Description
The function bootstrap_f2()
generates rr
bootstrap replicates
of the similarity factor based on resampling of complete profiles
(nonparametric bootstrap) or on resampling per time point the values
between profiles (parametric bootstrap). Estimates of “normal”,
“basic”, “student”, “percent” and of
“bias-corrected, accelerated” (BCa) percentile intervals are returned.
Usage
bootstrap_f2(
data,
tcol,
grouping,
rand_mode = "complete",
rr = 999,
each = 12,
new_seed = 100,
confid = 0.9,
use_ema = "no",
bounds = c(1, 85),
nsf = c(1, 2),
...
)
Arguments
data |
A data frame with the dissolution profile data in wide format. |
tcol |
A vector of indices that specifies the columns in |
grouping |
A character string that specifies the column in |
rand_mode |
A character string that indicates whether complete profiles
shall be randomised ( |
rr |
An integer that specifies the number of bootstrap replicates. The
default is |
each |
An integer that specifies the number of dissolution profiles to
be selected per group per randomisation round. The default is |
new_seed |
An integer for setting the seed for random number generation.
The default is |
confid |
A numeric value between 0 and 1 that specifies the confidence
limit for the calculation of the bootstrap confidence intervals. The
default is |
use_ema |
A character string that indicates whether the similarity
factor |
bounds |
A numeric vector of the form |
nsf |
A vector of positive integers that specify the “number
of significant figures” (nsf) of the corresponding values of the
|
... |
Named parameters of the functions |
Details
Information on can be found in at least three FDA
guidances and in the guideline of the European Medicines Agency (EMA)
“On the investigation of bioequivalence” (EMA 2010). For the
assessment of the similarity of dissolution profiles using the similarity
factor
according to the EMA guideline the following constraints
do apply:
A minimum of three time points (without zero) are necessary.
The time points should be the same for the two formulations.
For every time point and for each formulation at least 12 data points are required.
A maximum of one mean value per formulation may be > 85% dissolved.
The coefficient of variation (%CV) should be < 20% for the first time point and < 10% from the second to the last time point for any formulation.
Dissolution profiles are regarded as similar if the value is
between 50 and 100.
One often encountered problem is that the %CV constraint cannot be
fulfilled. One possibility in this situation is the use of the bootstrap
method (Shah 1998) by which the distribution of
is
simulated to obtain an unbiased estimate of the expected value of
and the variability of the underlying distribution. For the
calculation only those parts of the profiles are taken into account where
the means (per formulation) are
% dissolved (e.g.,
)
and a maximum of one mean value per formulation is
% dissolved.
In the literature it is suggested to make use of the lower 90% bias
corrected and accelerated (BCa) confidence interval (CI) limit to come to
a decision in terms of similarity (Stevens (2015)).
Value
An object of class ‘bootstrap_f2
’ is returned,
containing the following list elements:
Boot |
An object of class ‘ |
Profile.TP |
A named numeric vector of the columns in |
L |
A vector of the Jackknife leave-one-out-values. |
CI |
An object of class ‘ |
BCa_CI |
The lower and upper limits of the BCa interval calculated
by the |
Shah_BCa_CI |
The lower and upper limits of the BCa interval calculated according to Shah (Shah 1998). |
References
United States Food and Drug Administration (FDA). Guidance for industry:
dissolution testing of immediate release solid oral dosage forms. 1997.
https://www.fda.gov/media/70936/download
United States Food and Drug Administration (FDA). Guidance for industry:
immediate release solid oral dosage form: scale-up and post-approval
changes, chemistry, manufacturing and controls, in vitro dissolution
testing, and in vivo bioequivalence documentation (SUPAC-IR). 1995.
https://www.fda.gov/media/70949/download
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 2010; CPMP/EWP/QWP/1401/98 Rev. 1.
Stevens, R. E., Gray, V., Dorantes, A., Gold, L., and Pham, L. Scientific
and regulatory standards for assessing product performance using the
similarity factor, . AAPS Journal. 2015; 17(2):
301-306.
doi:10.1208/s12248-015-9723-y
Shah, V. P., Tsong, Y., Sathe, P., and Liu, J. P. In vitro dissolution
profile comparison - statistics and analysis of the similarity factor,
. Pharm Res. 1998; 15(6): 889-896.
doi:10.1023/A:1011976615750